Early tumor shrinkage and depth of response with first-line panitumumab or bevacizumab and mFOLFOX treatment in PARADIGM

Pembrolizumab + chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC): KEYNOTE-412

Futibatinib for intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements: Japanese sub-analysis of FOENIX-CCA2

Brexucabtagene Autoleucel in Relapsed/Refractory Mantle Cell Lymphoma (R/RMCL) in ZUMA-2: Durable Responder Analysis

Efficacy and safety of fruquintinib in Japanese patients with refractory metastatic colorectal cancer from FRESCO-2

MOMENTUM: Phase 3 Study of Momelotinib vs Danazol in Symptomatic and Anemic Myelofibrosis Patients post-JAK Inhibition

PD-1 blockade as curative intent therapy in mismatch repair deficient locally advanced rectal cancer

First Report of Cohort 3 and Mature Survival Data From the U31402-A-U102 Study of HER3‑DXd in EGFR-Mutated NSCLC

Sotorasib versus Docetaxel for Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation: CodeBreaK 200 Phase 3 Study

Adjuvant osimertinib in resected EGFR-mutated stage II–IIIA NSCLC: ADAURA Japan subgroup analysis

Phase II study of brigatinib in patients with TKI-naive ROS1-rearranged non-small cell lung cancer (NSCLC):Barossa study.

Phase 1b Efficacy of Telisotuzumab Vedotin and Osimertinib in Asian vs Non-Asian Patients With Advanced NSCLC

TROPION-Lung02: Initial Results of Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC

Overall survival results from the phase 3 TROPiCS-02 study of sacituzumab govitecan vs chemotherapy in HR+/HER2- mBC

T-DXd vs treatment of physician's choice in HER2+ mBC previously treated with T-DM1: primary results of DESTINY-Breast02